{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Mersana Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"MRSN"},"Address":{"label":"Address","value":"840 MEMORIAL DRIVE, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 498-0020"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines."},"CompanyUrl":{"label":"Company Url","value":"https://www.mersana.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brian DeSchuytner","title":"Senior VP, Chief Operating & Financial Officer"},{"name":"Martin H. Huber","title":"President, Chief Executive Officer & Director"},{"name":"Timothy B. Lowinger","title":"Senior VP, Chief Science & Technology Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}